The FDA has accepted Pfizer’s sNDA for review for an expanded indication for Xeljanz to include inhibition of progression of structural damage in the label. Xeljanz is a first in its class Janus Kinase inhibitor.
Your search for tofacitinib returned 56 results
Pfizer announced that the FDA has approved the supplemental New Drug Application (sNDA) for Xeljanz (tofacitinib citrate) to include additional patient-reported outcomes data in the label.
According to new research over 1 in 5 patients with inflammatory bowel disease (IBD) should have started treatment with an advanced systemic therapy earlier in their disease.
Vaccination rates in patients with rheumatoid arthritis remain poor “despite the high rates of infectious disease-related morbidity and mortality,” a review published in Clinical Opinion in Rheumatology has found.
The patient had been diagnosed with mild-to-moderate ulcerative colitis (UC) a month prior to presentation for which she was prescribed oral mesalamine.
Although found to increase the risk of infectious complications, janus kinase (JAK) inhibitors effectively induce clinical remission in patients with Crohn disease (CD) and clinical and endoscopic remission in patients with ulcerative colitis (UC), according to results of a recently published systematic review and meta-analysis.
- Loading...
